Pacer BioThreat Strategy ETF
VIRS
VIRS was delisted on the 10th of October, 2024.
6 hedge funds and large institutions have $3.21M invested in Pacer BioThreat Strategy ETF in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
507% more capital invested
Capital invested by funds: $528K → $3.21M (+$2.68M)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
20% more funds holding
Funds holding: 5 → 6 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.89M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$687K |
| 3 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$6.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7.51K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Osaic Holdings
Scottsdale,
Arizona
| $2.09M | +$1.89M | +55,530 | +1,227% |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $778K | +$687K | +20,202 | +942% |
|
3
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $271K | – | – | – |
|
|
LF
4
Lee Financial
Dallas,
Texas
| $51K | – | – | – |
|
|
AA
5
Ancora Advisors
Cleveland,
Ohio
| $11K | +$6.9K | +203 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $4K | -$7.51K | -221 | -63% |
|
VIRS Hedge Fund Activity: Q4 2021 in Review
6 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q4 2021, worth a combined $3.21M — up 507% from $528K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new VIRS positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Osaic Holdings, adding an estimated $1.89M. The largest seller was UBS Group, cutting an estimated $7.51K.
- 6 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q4 2021, up from 5 in Q3 2021.
- Funds reported $3.21M of Pacer BioThreat Strategy ETF stock for Q4 2021, up 507% quarter-over-quarter.
- 1 fund opened new Pacer BioThreat Strategy ETF positions in Q4 2021 and 0 closed out, a net change of +1 holder.
- The largest Pacer BioThreat Strategy ETF buyer in Q4 2021 was Osaic Holdings, an estimated $1.89M added.
- The largest Pacer BioThreat Strategy ETF seller in Q4 2021 was UBS Group, an estimated $7.51K sold.
Based on aggregated 13F filings for Q4 2021.